Pancytopenia Clinical Trial
Official title:
Lymphocytapheresis of Patients With Pancytopenia
Verified date | August 2020 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Aplastic anemia is a condition in which the cells normally found in blood are greatly
decreased. The normal levels of white blood cells, red blood cells, and platelets are much
lower in patients with aplastic anemia.
Because of these low levels of blood cells, patients with aplastic anemia have a variety of
immune system abnormalities. However, low levels of blood cells make it difficult to collect
specialized white blood cells (mononuclear cells) for research studies.
This study was designed to collect lymphocytes from patients with low levels of all blood
cells (pancytopenia) for use in research. Patients participating in the study will undergo a
special procedure known as lymphapheresis. During lymphapheresis blood is taken from the
patient in a manner similar to blood donation. The white blood cells are selectively removed
by spinning (centrifugation), and the remaining red blood cells and platelets are placed back
(re-infused) into the donor s blood stream.
Patients participating in this study will not benefit directly from it. However, cells
collected in this study may increase scientific knowledge and improve understanding and
treatment for diseases like aplastic anemia.
Status | Completed |
Enrollment | 38 |
Est. completion date | August 17, 2020 |
Est. primary completion date | January 19, 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: All patients with aplastic anemia or other bone marrow failure in which we would not expect to obtain 1 X 10(8) mononuclear cells from 100 mls of peripheral blood (i.e. an absolute lymphocyte count approximately less than 2000 per mm(3)). Age greater than or equal to 18. EXCLUSION CRITERIA: Patients unable to comprehend the investigational nature of the procedure. Patients unable to tolerate a temporary reduction of blood volume the equivalent of one unit of blood. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Goal was to obtain adequate numbers of cells for laboratory studies from pancytopenic patients in whom simple phlebotomy is inadequate. | To obtain enough cells if phlebotomy inadequate. | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05473650 -
Spectrum of Hematological Disorders in Pediatrics
|
||
Completed |
NCT00001398 -
Stem Cell Factor Medication for Aplastic Anemia
|
Phase 1 | |
Completed |
NCT00260689 -
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
|
Phase 2 | |
Completed |
NCT00000597 -
Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders
|
Phase 3 | |
Not yet recruiting |
NCT03521947 -
Management of Childhood Pancytopenia
|
||
Completed |
NCT00001399 -
Gene Therapy for the Treatment of Fanconi's Anemia Type C
|
Phase 1 | |
Completed |
NCT01187017 -
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
|
Phase 1/Phase 2 | |
Completed |
NCT01193283 -
Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
|
Phase 1/Phase 2 |